BASIC SCIENCE

2967888

PP01

Expression of inducible prostaglandin E synthase -1 (mPGES-1) is regulated by MAP kinase phosphatase-1

Tuure, Hämäläinen, Moilanen

2992069

PP02

MKP-1 as a novel factor in the pathogenesis of scleroderma. An experimental study

Scotece, Hämäläinen, Leppänen, Moilanen

2992069

PP03

TRPA1 as a factor in osteoarthritis: TRPA1 (Transient receptor potential ankyrin 1) mediates interleukin-6 expression in chondrocytes

Nummenmaa, Hämäläinen, Pemmari, Moilanen, Nieminen, Moilanen, Vuolteenaho, Moilanen

2995626

PP04

Myositis specific anti-histidyl tRNA synthetase (HisRS) autoantibodies display high reactivity against HisRS conformational epitopes and associate with lung and joint involvement

Cerqueira, Renard, Notarnicola, Wigren, Jakobsson, Graslund, Lundberg

2977490

PP05

Pyrazine-fused triterpenoids block TRPA1 ion channel in vitro and inhibit TRPA1-mediated inflammation in Vivo

Mäki-Opas, Hämäläinen, Moilanen, Haavikko, Ahonen, Alakurtti, Moreira, Muraki, Yli-Kauhaluoma, Moilanen

2977565

PP06

cAMP enhancing drugs salbutamol and rolipram augment the alternative activation of murine macrophages through MKP-1

Leppänen, Scotece,  Hämäläinen, Moilanen

3003868

PP07

Anti-inflammatory properties of the β2-receptor agonist salbutamol and the PDE4 inhibitor rolipram are mediated by MKP-1

Keränen, Hömmö, Hämäläinen, Leppänen, Moilanen, Korhonen

2983169

PP08

Self reported and performance-based physical function in patients with knee osteoarthritis

Demirtas, Bayram, Turgut

3004109

PP09

E74-like factor 3 (ELF3) is synergistically regulated by IL-17A and TNF and controls the production of inflammatory cytokines and matrix metalloproteinases in synovial fibroblasts

Kouri, Olkkonen, Ainola, Eklund, Nordström, Mandelin

2983487

PP10

Prostacyclin: a potential novel therapeutic target to treat tendon pain and inflammation

Bergqvist, Carr, Wheway, Watkins, Oppermann, Jakobsson, Dakin

3004115

PP11

Novel adipokine associated with osteoarthritis: retinol binding protein 4 is produced by cartilage and correlates with matrix metalloproteinases in osteoarthritis patients

Scotece, Koskinen-Kolasa,  Pemmari, Leppänen, Hämäläinen, Moilanen, Moilanen, Vuolteenaho

3004218

PP12

Transient Receptor Potential Ankyrin 1 (TRPA1) is an Inflammation-Induced Factor in Human Keratinocytes and Promotes the Expression of Inflammatory Genes in vitro

Luostarinen, Hämäläinen, Moilanen

3004219

PP13

IL-6 in osteoarthritis: effects of pinosylvin and monomethyl pinosylvin

Laavola, Leppänen, Hämäläinen, Vuolteenaho, Moilanen, Nieminen, Moilanen

INFLAMMATORY ARTHRITIDES

2955294

PP014

The relation between pain on functionality, quality of life and kinesiophobia in patients with ankylosing spondylitis

Tosun Aydin, Demirbuken, Kaya Mutlu

2999825

PP015

Increased Progression of Atherosclerosis in Patients with Rheumatoid Arthritis is Partially Reflected by Disease Severity at the Time of Diagnosis- 11-Year Prospective Follow-Up

Björsenius, Rantapää Dahlqvist, Wållberg-Jonsson, Södergren

3003425

PP016

Automated cell phone monitoring of disease activity and medication problems in early rheumatoid arthritis

Kuusalo, Sokka, Pirilä, Kautiainen, Puolakka

2968971

PP017

Marginal jawbone loss is associated with onset of rheumatoid arthritis and is related to plasma level of receptor activator of nuclear factor kappa-B ligand (RANKL)

Johansson, Kindstedt, Palmqvist, Koskinen-Holm, Kokkonen, Johansson, Lundberg, Rantapää Dahlqvist

3003686

PP018

A mass cytometry insight to synovial fluid of rheumatoid arthritis

Sandnes, Bader, Svanes Fevang, Gavasso

2969846

PP019

Vitamin D in individuals before onset of rheumatoid arthritis - relation to Vitamin D binding protein and its associated genetic variants

Brink, Johansson, Nygren, Ärlestig, Hultdin, Rantapää Dahlqvist

2969873

PP20

Intensive treatment of rheumatoid arthritis patients prevents myocardial abnormalities - a cardiac magnetic resonance follow-up study

Koivuniemi, Holmström, Kivistö, Kuuliala, Kautiainen, Hämäläinen, Eklund, Rajamäki, Moilanen, Leirisalo-Repo

3003889

PP21

Fatigue, pain and patient global assessment are poorly interconnected and poorly explained by other clinical outcome measures in individual patients with psoriatic arthritis

Rintek Madsen

2973291

PP22

Predictors for clinically diagnosed gout – 30 years follow-up in the Malmö Preventive Project cohort Sweden

Kapetanovic, Nilsson, Turesson, Englund, Dalbeth, Jacobsson

3003896

PP23

Expression of Uncoupling Protein-1 in subcutaneous fat reduces the total cholesterol level and cardiovascular risk in female RA patients

Lyngfelt, Erlandsson, Nadali, Andersson, Silfverswärd, Pullerits, Bokarewa

2973640

PP24

Predictors of drug survival of abatacept in rheumatoid arthritis – results from a large national quality register cohort study

Cagnotto, Willim, Nilsson, Saevarsdottir, Turesson

3003904

PP25

Patient and physician global assessments reflect strongly diverging attitudes between patients with psoriatic arthritis and their rheumatologists to severity of disease and to the relative importance of different outcome measures

Rintek Madsen

3003909

PP26

Physical functioning in rheumatoid arthritis is controlled by hippocampus and IGF1 receptor signaling

Andersson, Wasen, Silfverswärd, Leifsdottir, Erlandsson, Heckemann, Kalm, Bokarewa

2977679

PP27

Quality of life and disease activity of transition phase patients with juvenile idiopathic arthritis and adult onset rheumatic diseases

Relas, Kosola

3004113

PP28

Hydroxychloroquine improves the blood lipid profile in RA and SLE after four and eight weeks of treatment. A randomized interventional study

Bengtsson, Wahlin, Braune, Jönsson, Wållberg-Jonsson

2981240

PP29

Durability, maintenance and effects of dose reduction following prolonged treatment with baricitinib

Smolen, Dougados, Takeuchi, Genovese, Haraou, Klar, Kavanaugh, Alonso, Dudler, Taylor, Nash, Zerbini, Durez, Pum, Arthanari, De Leonardis, van Vollenhoven, E Larsson

3004212

PP30

Risk for work disability in incident patients with rheumatoid arthritis and spondyloarthritis varies between health care districts in Finland – an indicator of treatment effectiveness?

Puolakka, Kautiainen, Rantalaiho, Virta, Sokka, Haanpää

2981305

PP31

Summary of baricitinib effect on patient-reported outcomes (PROs) in methotrexate–inadequate responder patient population

M Dougados, Fautrel, Van De Laar, Kirkham, Alten, Cseuz, Smolen, Sanchez-Burson, Bird, Scheinberg, Van Den Bosch, Barry, Durand, Zhu, De Leonardis, Taylor, Larsson

3004216

PP32

Evaluation of serum protein levels at baseline as predictors of response to methotrexate in patients with early rheumatoid arthritis: results from SWEFOT trial population

Hambardzumyan, Hamsten, Idborg, Lourido, Saevarsdottir, Nilsson, van Vollenhoven, Jakobsson

2981331

PP33

Safety summary results of baricitinib focusing on serious infections events and preselected comorbidities

Combe, Balsa, Winthrop, Tony, Genovese, Harigai, Smolen, Emery, Dudler, Hall, Zerbini, Van Den Bosch, Durand, Arthanari, Rogai, Zhong, Meszaros, Dougados, Larsson

3004289

PP34

First line TNFα-inhibitor therapy reduces NSAID need in patients with rheumatic diseases

Palsson, Love, Gunnarsson, Gudbjornsson

3004290

PP35

Recognizing imminent rheumatoid arthritis - Survivin measurement and defined clinical symptoms predicts transition from arthralgia to rheumatoid arthritis

Silfverswärd, Erlandsson, Turkkila, Pullerits, Bokarewa

2981552

PP36

Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naïve subjects with active psoriatic arthritis

Mease, Gladman, Davenport, Zhou, Guerette, Teng, Kaura, Nash

2982578

PP37

Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 5.5 years: an updated integrated safety analysis

Genovese, Smolen, Takeuchi, Hyslop, Macias, Rooney, Chen, Dickson, Riddle, Cardillo, Ishii, Winthrop, E Larsson

2982731

PP38

Do sacroiliac joint pain provocation tests identify inflammation in patients with non-radiographic axial spondyloarthritis?

Castro, Stebbings, Milosavljevic, Juhl Pedersen, Bussey

2983188

PP39

Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from two phase 3 studies (FUTURE 2 and FUTURE 3)

Wallman, Schett, McInnes, Quebe-Fehling, Rasouliyan, Pricop, Gaillez, Fasth

2983218

PP40

Metabolic and inflammatory markers in patients with newly diagnosed inflammatory joint diseases

Kononoff, Hörkkö, Pussinen, Kautiainen, Elfving,  Savolainen, Arstila, Niinisalo, Hämäläinen, Vuolteenaho, Moilanen, Rutanen, Marjoniemi, Kaipiainen-Seppänen

2983472

PP41

Analysis of 157 pneumonia episodes in Finnish children with juvenile idiopathic arthritis

Salonen, Säilä, Salonen, Helminen, Linna, Kauppi

OSTEOARTHRITIS AND CRYSTAL ARTHRITIDES

3003867

PP42

Gene expression in adverse reaction to metal debris around metal-on-metal arthroplasty: an RNA-Seq-based study

Pemmari, Leppänen, Paukkeri, Eskelinen, Moilanen, Moilanen

2953306

PP43

Relationship between calcium pyrophosphate dihydrate crystal and operated knee osteoarthritis -gender specific analyses

Nishikawa, Takami, Owaki, Fuji

3004160

PP44

The relationship between the kinesiophobia and functional level in patients with gonarthrosis

Tascilar, Kaya, Kuyucu, Erdil

2974189

PP45

Can we predict inadequate-response to allopurinol dose escalation? analysis of a randomised controlled trial

Stamp, Chapman, Barclay, Horne, Tan, Drake, Dalbeth

2977498

PP46

No associations between structural changes on radiography, pain and muscle strength in patients with knee osteoarthritis

Kaya Mutlu, Analay Akbaba, Tosun Aydin

CLINICAL SCIENCE;
OTHER

2981561

PP47

Cytokine effects of apremilast as a mechanism of efficacy in systemic-naive subjects with moderate plaque psoriasis: results from the UNVEIL trial

Strober, Alikhan, Lockshin, Schafer

2982189

PP48

Bone healing of atypical femoral fractures treated by teriparatide and/or low-intensity pulsed ultrasound therapy in the patients with rheumatic diseases in North Japan

Takakubo, Miyaji, Naganuma, Oki, Ito, Ota, Sasaki, Takagi

3003513

PP49

Administration of opioid analgesics in the Finnish elderly population – a population based study

Marttinen, Kautiainen, Haanpää, Pohjankoski, Vuorimaa, Hintikka, Kauppi

2982199

PP50

Efficacy and safety of ixekizumab at week 24 in biologic experienced patients with active psoriatic arthritis summary results

Marzo-Ortega, Meroni, Agirregoikoa, Behrens, Bradley, Liu Leage, Garcia, Sapin, Ho, Constantin, Hall, Porsdal

3003903

PP51

Skeletal troponin I concentrations in different patient cohorts

Bamberg, Lundberg, Pirilä, Paltta, Mali, Nordling, Strandberg, Strandberg, Pettersson

2982234

PP52

Efficacy and safety of ixekizumab at week 52 in biologic naïve patients with active psoriatic arthritis (SPIRITP1)

Lespessailles, Kirkham, Nebro, Alonso, Strehblow, Inciarte, Porsdal, Garcia, Kurzawa, Sapin, Geussens, Goupille, Tahir

2983140

PP53

Evaluation of pain, general health perception and physical function in patients with Behçet’s disease

Demirtas, Yasar Bilge, Korkmaz

SYSTEMIC CONNECTIVE TISSUE DISEASES AND VASCULITIDES

2962642

PP54

Giant cell arteritis - a report on systematic physical evaluation and large vessel involvement as a prognostic risk factor for complicated disease course

Naderi

3004211

PP55

The role of anti-inflammatory lipid mediators on vascular maintenance in human resistance sized arteries upon mPGES-1 inhibition

Steinmetz, Arefin, Mudrovcic, Bergqvist, Larsson, Korotkova, Kublickiene, Jakobsson

2978665

PP56

Immunoglobulin A anti-phospholipid antibodies in Swedish cases with systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual

Frodlund, Vikerfors, Elvin, Rönnelid, Svenungsson, Sjöwall

3004265

PP57

Usage of drugs for cardiovascular diseases is higher in SLE patients already before diagnosis

Elfving, Kautiainen, Virta, Kaipiainen-Seppänen, Puolakka

2979623

PP58

Soluble urokinase plasminogen activator receptor (suPAR) predicts the development of organ damage over 5 years in systemic lupus erythematosus: results from the SLICC inception cohort

Enocsson, Wirestam, Wetterö, Skogh, the SLICC group, Bruce, Sjöwall

3006353

PP59

Microparticles as potential biomarkers of disease activity in anti-neutrophil cytoplasmic antibody – associated vasculitis

Antovic, Mobarrez, Nordin, Gunnarsson

2982742

PP60

Autoimmune liver disease among well-characterized patients with systemic lupus erythematosus

Heijke, Frodlund, Kechagias, Sjöwall

EPIDEMIOLOGICAL SCIENCE; OTHER

2983647

PP61

Elevated erythrocyte sedimentation rate at time of diagnosis is associated with high mortality in patients with idiopathic inflammatory myopathies: a register based study

Espinosa Ortega, Ajeganov, Alexanderson, Lundberg

2983689

PP62

Patients fulfilling ESSG-criteria but not ASAS criteria for spondylartritis

Hansen

3003675

PP63

Active first year treatment of early rheumatoid and unspecified arthritis

Muilu, Rantalaiho, Kautiainen, Virta, Eriksson, Puolakka

3004214

PP64

Mortality rate in a nationwide inception cohort of rheumatoid arthritis compared to population controls - seropositivity still translates into shortened survival

Puolakka, Kautiainen, Virta, Rantalaiho

3004246

PP65

Hyperuricemia is very common in aging Finnish population – especially among men

Kauppi, Kerola, Kautiainen, Vaskivuo, Kauppi

EPIDEMIOLOGICAL SCIENCE
TREATMENT REGISTERS

3001518

PP66

One-year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator.
An observational DANBIO study

Glintborg, Sørensen, Omerovic, Mehnert, Manilo, Danebod, Jensen, Nordin, Hendricks, Loft, Chrysidis, Andersen, Raun, Lindegaard, Espesen, Jakobsen, Hansen, Dalgaard, Pedersen, Kristensen, Linauskas, Andersen, Grydehøj, Krogh, Hetland

3001783

PP67

One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the DANBIO registry

Glintborg, Sørensen, Omerovic, Mehnert, Manilo, Danebod, Jensen, Nordin, Hendricks, Loft, Chrysidis, Andersen, Raun, Lindegaard, Espesen, Jakobsen, Hansen, Dalgaard, Pedersen, Kristensen, Linauskas, Andersen, Grydehøj, Krogh, Hetland

3003503

PP68

Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient health care resources? A register-based study in patients with inflammatory arthritis

Glintborg, Sørensen, Hetland

IMAGING

2979324

PP69

Assessment of vascular dimensions using non-invasive very-high resolution ultrasound in patients with suspected giant cell arteritis

Sundholm, Pettersson, Paetau, Albäck, Sarkola

3004209

PP70

Radiographic features of psoriatic arthritis mutilans– results from the Nordic PAM-Study

Laasonen, Lindqvist, Iversen, Ejstrup, Stahle, Gudbjornsson

2983180

PP71

Clinical impact of 18FDG-PET/CT in diagnosis of suspected vasculitis -A prospective study

Taimen, Kemppainen, Hohenthal, Salomäki, Mali, Kajander, Palomäki, Pirilä

OTHER

2984287

PP72

Inclusion body myositis and T-cell large granular lymphocytic leukaemia. An underestimated coexistence of two severe disorders: A report of two cases.

Morillon, Iversen, Korsholm, Plesner, Diederichsen

2981448

PP73

Prolongation or discontinuation of TNF inhibitors in the treatment of rheumatoid arthritis. Could this be a realistic scenario?

Kaltsonoudis, Pelechas, Voulgari, Drosos

3001929

PP74

EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis

Kukkurainen, van Eijk-Hustings, Kauppi

3004104

PP75

A psycho-educational path for patient affected by fibromyalgia

Romeo, Schembari, Caceci, Raiti, Birrico, Torneo

3004213

PP76

Case report: bowel-associated dermatosis-arthritis syndrome with myositis-like features

Pelttari, Jernman, Porre, Palmio, Latva-Hirvelä, Isomäki, Rantalaiho, Uotila